02/102020

Authoritative expert interview of "enoxaparin" (4)

Q:youalsomentionedthatlowmolecularweightheparinisderivedfromcommonheparin.Couldyoupleaseexplainthegeneralityanddifferenceoflowmolecularweightheparininclinicalapplication?A:althoughalllowmolecularweigh

Click to view

02/072020

Authoritative expert interview of "enoxaparin" (3)

Q:whichdiseasesaremoresuitableforenoxaparintreatmentinclinic?A:alargenumberofhigh-qualityclinicalstudiesbasedonxaihaveestablishedthatenoxaparinisanidealchoiceforpatientswithstable/unstableanginaandst-

Click to view

02/062020

Authoritative expert interview of "enoxaparin" (2)

Q:howcanweevaluateanticoagulantsinacomprehensivewaytohelpselecttherightdrugforclinicaluse?Answer:thechoiceofanticoagulantdrugsinclinicaltreatmentshouldstrictlyfollowthedrugindications,evidenceandtreat

Click to view

02/052020

Interview with authoritative experts on "enoxaparin" (1)

Q:anticoagulanttherapyisanimportantpartofcardiovasculartherapy,andeveryadvanceinthefieldofanticoagulationiscriticaltotheclinic.Thestatefoodanddrugadministrationchangedthegeneralnameofkexai®from"lowmol

Click to view

01/312020

Usage and dosage of enoxaparin sodium slowly chat (1)

Comparedtonon-cancerpatientswhounderwentsimilarsurgeryTheriskofVTEincancerpatientsis4-6timeshigherthaninnon-cancerpatientsPatientsreceivingchemotherapyhada6.5foldincreasedriskofVTETheriskofDVTincancer

Click to view

News and information